Key Takeaway: Werewolf Therapeutics, Inc. has reported its financial results for the second quarter of 2023, highlighting its innovative work in developing conditionally activated therapeutics aimed at cancer treatment. The company also provided a business update, emphasizing its commitment to stimulating the immune system. The financial performance reflects growth and potential in its therapeutic pipeline.
Price reaction · baseline $2.53 (2023-08-09 close) · hit pre-market · clean, no other HOWL news in the window
day 0 close
+4%
day 1
+3.2%
day 3
-0.8%
Market Sentiment Analysis
POSITIVE FACTORS
Innovative approach to cancer treatment
Focus on conditionally activated therapeutics
Positive financial results for the second quarter
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the second quarter ended June 30, 2023.
Frequently Asked Questions
What financial results did Werewolf report for Q2 2023?
Werewolf Therapeutics reported its financial results for the second quarter of 2023.
What is the focus of Werewolf Therapeutics?
The company focuses on developing conditionally activated therapeutics for cancer treatment.
When did Werewolf Therapeutics report its Q2 results?
The Q2 financial results were reported for the period ending June 30, 2023.